Loading
Virology and Viral Diseases / Parasitic Diseases Research and Treatment · Review
Journal of Clinical and Diagnostic Research · August 5, 2026
A consensus or society position rather than new primary data.
This is a narrative review of Nipah virus epidemiology, pathogenesis, clinical manifestations, and emerging preventive and therapeutic strategies. It identifies current gaps—absence of licensed antivirals or vaccines, need for rapid diagnostics, and strengthened surveillance—and recommends collaborative international frameworks and integrated One Health approaches, but does not report primary clinical trial or observational data.
Narrative review. Patients in endemic regions affected by Nipah virus outbreaks; vaccine and therapeutic candidates in preclinical and early clinical phases.
Nipah virus is an emerging zoonotic pathogen of the Paramyxoviridae family first identified in 1998, associated with high morbidity and mortality from severe encephalitis and respiratory illness Current management is largely supportive with no licensed antivirals or vaccines available Remdesivir and monoclonal antibodies have shown promising efficacy in preclinical studies
No quantitative data on morbidity, mortality, transmission rates, or outbreak frequency reported Nipah virus is an emerging zoonotic pathogen of the Paramyxoviridae family first identified in 1998, associated with high morbidity and mortality from severe encephalitis and respiratory illness
This review underscores that no licensed therapeutics or vaccines currently exist for Nipah virus and emphasizes the urgency of developing rapid diagnostics, strengthening surveillance, and implementing coordinated international research and public health responses to prevent spillover and manage outbreaks.
A narrative review synthesizing current knowledge on Nipah virus epidemiology, pathogenesis, clinical management, and emerging strategies, identifying research gaps and recommending integrated public health approaches rather than reporting primary clinical evidence.
As stated by the source record.
This review underscores that no licensed therapeutics or vaccines currently exist for Nipah virus and emphasizes the urgency of developing rapid diagnostics, strengthening surveillance, and implementing coordinated international research and public health responses to prevent spillover and manage outbreaks.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Nipah virus (NiV) is known to be an emerging zoonotic pathogen of the Paramyxoviridae family, which was first identified in 1998, and is also associated with high morbidity and mortality due to severe encephalitis and respiratory illness. Transmission occurs through direct contact with infected animals, contaminated food, and human-to-human transmission, thereby further highlighting its epidemic potential. Despite significant advances in understanding its virology, pathogenesis, as well as clinical manifestations, NiV outbreaks continue to pose substantial public health challenges, usually in endemic regions. Current management of NiV remains largely supportive with no licensed antivirals or vaccines available, thus emphasising the need for effective medical countermeasures. Recent therapeutic developments must focus on monoclonal antibodies and antiviral agents, including Remdesivir, which have shown promising efficacy in preclinical studies. Vaccine candidates, including recombinant protein, viral vector, and mRNA-based platforms, are being examined in their early phases of clinical evaluation, showing potential for robust protection of immunity. Future research priorities must include the development of rapid point-of-care diagnosis, strengthening genomic surveillance while also implementing One Health approaches integrating human, animal and environmental data for the prevention of spillover events. Refining animal models and elucidating immune correlates of protection are very important aspects for translating preclinical successes into adequately licensed interventions for management approaches for NiV. Collaborative international frameworks as well as structured R&D roadmaps are critical options for the acceleration of vaccine and therapeutic development, thereby further ensuring rapid deployment during outbreaks. This narrative review article highlights current knowledge on the epidemiology of NiV, pathogenesis, clinical management, as well as emerging preventive-therapeutic strategies while also identifying critical research gaps. It underscores the need for a proactive, integrated approach which combines medical, public health and scientific efforts for the mitigation of the threat of NiV globally.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.